No Data
No Data
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of Its Oral Drug Piclidenoson With FDA & EMA-Approved Protocol
XCan-Fite Partner Vetbiolix Accelerate Piclidenoson Development With Clinical Trial For Canine Osteoarthritis
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development With Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
12 Health Care Stocks Moving In Wednesday's Intraday Session
Can-Fite Biopharma Shares Are Trading Lower. The Company Announced a Phase II Design Is Completed and Preparatory Work Is Undergoing for the Initiation of Clinical Study in the Rare Genetic Disease Lowe Syndrome.
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome With Piclidenoson